Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00110864
Status:
COMPLETED
Last Update Posted:
2007-08-23
First Post:
2005-05-13
Brief Title:
Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
Sponsor:
Wellstat Therapeutics
Organization:
Wellstat Therapeutics
Study Overview
Official Title:
A Phase 2 Randomized Double-Blind Placebo-Controlled Multicenter Study of the Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent type 2 diabetics as measured by the change in average daily insulin dose from baseline to week 12 The effects of PN2034 on HbA1c fasting plasma glucose FPG and lipid levels will also be measured
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None